Last reviewed 2026-04-20 · How we verify

Sanabolicum (NANDROLONE CYCLOTATE)

Phase 2 active Small molecule

Sanabolicum (generic name: NANDROLONE CYCLOTATE) is a Androgen drug. It is currently in Phase 2 development.

Sanabolicum works by binding to androgen receptors in the body, which can influence the development and maintenance of male characteristics.

Sanabolicum, also known as NANDROLONE CYCLOTATE, is an androgenic small molecule drug. Its exact target is unknown, but it is classified as an androgen, which suggests it may interact with androgen receptors. Sanabolicum's commercial status and approved indications are unclear, and it is not known whether it is FDA-approved or off-patent. As an androgen, Sanabolicum may be used to treat conditions related to hormone imbalances, but its specific uses and safety considerations are not well-documented. Further research is needed to fully understand this drug's properties and potential applications.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	NANDROLONE CYCLOTATE
Drug class	Androgen
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Think of androgen receptors like locks on a door. Sanabolicum is a key that fits into these locks, allowing it to influence the activity of cells that respond to androgens, such as testosterone. This can lead to changes in the body, including the development of male characteristics like muscle growth and facial hair.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Sanabolicum CI brief — competitive landscape report
Sanabolicum updates RSS · CI watch RSS

Frequently asked questions about Sanabolicum

What is Sanabolicum?

Sanabolicum (NANDROLONE CYCLOTATE) is a Androgen drug.

How does Sanabolicum work?

Sanabolicum works by binding to androgen receptors in the body, which can influence the development and maintenance of male characteristics.

What is the generic name of Sanabolicum?

NANDROLONE CYCLOTATE is the generic (nonproprietary) name of Sanabolicum.

What drug class is Sanabolicum in?

Sanabolicum belongs to the Androgen class. See all Androgen drugs at /class/androgen.

What development phase is Sanabolicum in?

Sanabolicum is in Phase 2.

Drug class: All Androgen drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing